Hexarelin
Also called Examorelin, EP-23905
No single human route established in this referenceHuman study reference
Research reference
Human study
Hexarelin short-term route study
Separate groups: 1.25 mg intranasally three times daily, or 20 mg orally three times daily
8 days for the nasal group; 15 days for the oral group
Hexarelin oral/intranasal study (1996) ↗When results may show
- When change was measured
- GH responsiveness and IGF-I were examined, not a validated muscle-gain timeline.
- When to assess
- 8 days for the nasal group; 15 days for the oral group
- Conditions and limitations
- Two small healthy older-adult groups. These route-specific amounts must not be copied into an under-the-skin plan. No universal amount, long course or cycling rule is inferred.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C47H58N12O6
- Mol. weight
- 887 Da
- CAS
- 140703-51-1
- PubChem CID
- 6918297
External references
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 5hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Hexarelin oral/intranasal study (1996)These route-specific amounts must not be copied into an under-the-skin plan. No universal amount, long course or cycling rule is inferred.